Background Waning of vaccine protection against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The …

Background The protection conferred by natural immunity, vaccination, and both against
symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the …

Protection against Omicron by Previous SARS-CoV-2 Infection Using a national Covid-19
database in Qatar, investigators found that previous SARS-CoV-2 infection provided protection …

Background Waning of vaccine protection against coronavirus disease 2019 (Covid-19)
and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory …

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna)
vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-…

SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted
a matched, test-negative, case-control study to estimate duration of protection of the second …

Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5
Subvariants | NEJM Skip to main content NEJM Group Follow Us Facebook Twitter Instagram …

With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant,
we conducted a matched test-negative case–control study to assess the real-world …

Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has been documented, raising public health concerns. SARS-CoV-2 reinfections were …

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2 | NEJM Skip to
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …